Physician profile
Wesley Palmer
NPI 1235111923
$4,212.35
in general payments reported to CMS, 2019-2025
29 companies · $482 in 2025
The $482 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $503 · 2021: $815 · 2022: $995 · 2023: $765 · 2024: $394 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,486 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.40 |
| Education | $155.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $627.00 | 2020-2025 | |
| Novo Nordisk INC | $518.28 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $338.13 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $335.72 | 2019-2025 | Farxiga, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $334.02 | 2020-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $304.89 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $213.99 | 2019-2022 | |
| Astellas Pharma US INC | $186.49 | 2023-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.88 | 2020-2024 | Jardiance |
| Glaxosmithkline, LLC. | $158.36 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $107.95 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $103.86 | 2019-2023 | |
| Lilly USA, LLC | $81.15 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $78.54 | 2023-2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $71.15 | 2022-2024 | Quviviq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $69.28 | 2019-2022 | |
| Amarin Pharma, INC. | $67.29 | 2020-2021 | |
| Amgen INC. | $65.96 | 2022-2023 | Repatha, Otezla |
| Tactile Systems Technology INC | $61.05 | 2021-2024 | Flexitouch Plus, Entre Plus |
| Regeneron Healthcare Solutions, INC. | $49.18 | 2021 | |
| Urovant Sciences INC | $42.61 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $41.86 | 2022-2025 | Zoryve |
| Exact Sciences Corporation | $41.67 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $40.78 | 2019-2020 | |
| Esperion Therapeutics, INC. | $32.02 | 2021-2022 | |
| Baxter Healthcare | $18.08 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.74 | 2023 | |
| Genentech USA, INC. | $14.11 | 2020 | |
| Phathom Pharmaceuticals, INC. | $13.31 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Palmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.